Pages

▼
Tuesday, May 9, 2023

Dompé Starts GLADIATOR, a Phase-III Clinical Trial of Ladarixin

›
Ladarixin is a drug being develop by Dompé (an Italian company).  It inhibits activity on parts of the immune system called the IL-8 recepto...
1 comment:
Friday, April 7, 2023

T1D Research News (Quick Bits from April)

›
This blog covers three pieces of news which do not apply directly to cure focused research, but which I found interesting anyway. Tight Hone...
Friday, March 31, 2023

Results from a Phase-II Verapamil Study

›
Verapamil is a drug which has been used in the US since 1982 for high blood pressure, migraines, and heart problems.  It also lowers levels ...
Monday, March 20, 2023

Influenza Vaccination Starts a Phase-II? Clinical Trial

›
This is a straight forward clinical trial: people recently diagnosed with type 1 diabetes (in their honeymoon phase) will be given a standar...
Monday, February 27, 2023

Ixekizumab (Taltz) Starts a Phase-II? Trial In Honeymooners

›
Ixekizumab, sold under the trade name Taltz, blocks a specific part of the immune system called Interleukin 17 (IL-17).  It has been approve...
Thursday, February 9, 2023

OPT101 Starts A Phase-I Trial in Adults with Established T1D

›
OPT101 is a peptide derived from mouse CD154.  What does that mean?  A peptide is a small part of a protein.  CD154 is a protein found on so...
1 comment:
Monday, December 26, 2022

Youtube Video Describing How JDRF Makes Funding Decisions

›
If you care about research aimed at curing type-1 diabetes, then you should care about JDRF's research funding.  Year after year, they f...